Phase 1/2a Study of ANPD001 in Parkinson Disease

Enrolling by Invitation

PHASE1Ages 40–75InterventionalTreatment

Aspen Neuroscience

~9 participants

Updated 2026-05-14 on ClinicalTrials.gov

What's tested:ANPD001Custom Device

At a glance

Recruiting sites

0 of 9 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Incidence and severity of treatment emergent adverse events (Safety and Tolerability)

Measured over 1 year (primary follow up)

Conditions

Parkinson Disease

NCT06344026

Where you'd take part

This study runs at 9 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Emory University
Atlanta, Georgiano site contact published
Feinstein Institutes
Manhasset, New Yorkno site contact published
Scripps Health
La Jolla, Californiano site contact published
University of Arizona - Banner Health
Tucson, Arizonano site contact published
University of California, Irvine
Orange, Californiano site contact published
University of California, Los Angeles
Los Angeles, Californiano site contact published
University of California, San Diego
San Diego, Californiano site contact published
University of California, San Francisco
San Francisco, Californiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Revati Shreeniwas, MD, FCCP · STUDY_CHAIR · Aspen Neuroscience

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Age 40-75 years of age at time of consent in the trial-ready cohort study ANPD001-01

Met all eligibility requirements for inclusion in the trial-ready cohort in clinical study ANPD001-01

Diagnosed with Parkinson Disease at least 4 years ago

Unequivocal motor response to Levodopa

Exclusion

Prior brain surgery that, in the opinion of the neurologist or neurosurgeon, contraindicates administration of ANPD001

History of intracranial therapy for PD, including deep brain stimulation (DBS), focused ultrasound (FUS), gene therapy or other biological therapy

History of cognitive impairment or dementia

History of clinically significant Dopa Dysregulation syndrome

History of epilepsy, stroke, multiple sclerosis, poorly controlled or progressive neurological disease (other than PD), or poorly controlled cardiovascular disease

Inability to temporarily stop anticoagulation or antiplatelet therapy for at least 2 weeks

History of malignancy (cerebral or systemic) within the prior 5 years, except treated cutaneous squamous or basal cell carcinomas

Contraindication to MRI / contrast CRT and/or use of contrast agents

Weight \> 300 lbs or Body Mass Index (BMI) \> 35

Newly diagnosed diabetes (HbA1c \> 7.0%), uncontrolled diabetes \> 8.0% requiring frequent medication changes, or any other acute or chronic medical condition that would significantly increase the risks of a neurosurgical procedure

Pregnancy or lactation

Significant drug-induced dyskinesia (\> 3 for any body part on the Abnormal Involuntary Movement Scale \[AIMS\])

Male or female with reproductive capacity who is unwilling to use barrier contraception for 3 months post-administration of the investigational product

Unable to comply with the protocol procedures, including frequent and prolonged follow-up assessments

Any significant issue raised by the neurologist or neurosurgeon

What this trial measures

Incidence and severity of treatment emergent adverse events (Safety and Tolerability)1 year (primary follow up)
incidence and severity of treatment emergent adverse events (TEAE) and serious adverse events (SAE)

Trialytics